Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Yukari Tsubata et al.|The Lancet Oncology|2019Cited by 642
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Makoto Maemondo, Tatsuro Fukuhara et al.|Institutional Repositories DataBase (IRDB)|2022Cited by 109
Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority TrialAkihiro Nomura, Kohta Satake, Tomoyuki Tanigawa et al.|Journal of Medical Internet Research|2019Cited by 77
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Makoto Maemondo, Haruhiro Saito et al.|EBioMedicine|2020Cited by 30
Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505Isamu Okamoto, Kazuhiko Nakagawa, Takashi Nishimura et al.|Clinical Cancer Research|2008Cited by 26